Although several early drugs targeting HER2 had poor efficacy in NSCLC [34,36,45], the advent of newer-generation HER2-targeting drugs such as poziotinib [78] and pyrotinib [79,80] exhibited good antitumor effects in clinical trials. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.